In March 2025, the company introduced new strategies for a immediate-to-consumer giving of its Wegovy weight loss drug. The company recognized a fresh pharmacy, referred to as NovoCare, which might charge consumers $499 a month for use of the drug, less than 50 % the price of the drug through other pharmaceutical distribution networks.[fifty three]